Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1840 • ACR Convergence 2025
Breathomics in Systemic Lupus Erythematosus: uncovering non-invasive markers of disease activity
Lorenzo Beretta¹, Martina Iacubino², Lorenzo Rocco³, Alexandre Voskuijl⁴, Marta Alarcon-Riquelme⁵, Guillermo Barturen⁶, LIam Grimmett⁷, Matt Kerr⁷, Chiara Bellocchi³, Barbara Vigone⁸, Alessandro Santaniello⁸ and Ioannis Parodis⁹, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, ²UNIMI, Milano, Milan, Italy, ³University of Milan, Milan, Italy, ⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ⁵Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁶Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ⁷Owlstone Medical, Cambridge, United Kingdom, ⁸Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ⁹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden
Background/Purpose: 3TR (taxonomy, treatment, targets and remission) aims to provide insights into the mechanisms of response and non-response to treatment in systemic autoimmune diseases, including…
Abstract Number: 1759 • ACR Convergence 2025
Role of a pathogenic bacterial factor produced by a human gut pathobiont in inducing platelet activation and thrombo-inflammation.
Abhimanyu Amarnani¹, Cristobal F. Rivera², Susan RS Gottesman³, Zakia Azad¹, Mingyang Yi⁴, Joshua Prasad⁴, Cynthia Loomis⁴, Andy Lee⁴, Nimat Ullah⁴, Bhama Ramkhelawon⁵ and Gregg J. Silverman¹, ¹New York University Grossman School of Medicine, New York, NY, ²New York University Grossman Department of Surgery, New York, ³SUNY Downstate Health Sciences University, New York, ⁴New York University Grossman School of Medicine, New York, ⁵New York University Department of Surgery, New York
Background/Purpose: SLE is an autoimmune disease that causes progressive multi-organ damage, leading to renal injury, or lupus nephritis (LN), in half of patients. Despite treatment,…
Abstract Number: 1696 • ACR Convergence 2025
A multi-omics resource of B cell activation reveals genetic mechanisms for autoimmune diseases
Vitor Aguiar¹, Marcella Franco¹, Nada Abdel Aziz¹, Daniela Fernandez-Salinas², Marcos Chinas¹, Mariasilvia Colantuoni², Qian Xiao¹, Nicolaj Hackert¹, Yifei Liao³, Rodrigo Cervantes-Diaz¹, Marc Todd¹, Brian Wauford¹, Alex Wactor¹, Vaishali Prahalad¹, Raquel Laza-Briviesca¹, Roxane Darbousset¹, Qiang Wang¹, Scott Jenks⁴, Kevin Cashman⁴, Esther Zumaquero⁴, Zhu Zhu¹, Junning Case³, Paloma Cejas⁵, Miguel Munoz-Gomez⁵, Hannah Ainsworth⁶, Miranda Marion⁷, Mehdi Benamar¹, Pui Lee⁸, Lauren Henderson⁹, Margaret Chang², Kevin Wei¹⁰, Henry Long⁵, Carl Langefeld¹¹, Benjamin Gewurz³, Ignacio Sanz⁴, Jeffrey Sparks¹², Esra Meidan¹³, Peter Nigrovic² and Maria Gutierrez-Arcelus², ¹Boston Children's Hospital, Boston, ²Boston Children's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Emory University, Atlanta, ⁵Dana Farber Cancer Institute, Boston, ⁶Wake Forest University, Winston-Salem, NC, ⁷Wake Forest, Winston-Salem, ⁸Boston Children's Hospital, Newton, MA, ⁹Boston Children's Hospital, Watertown, MA, ¹⁰Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ¹¹Wake Forest University School of Medicine, Winston Salem, NC, ¹²Brigham and Women's Hospital, Boston, MA, ¹³Boston Children's Hospital, Somerville, MA
Background/Purpose: Most genetic variants that confer risk of complex autoimmune diseases affect gene regulation in specific cell types. Their target genes and focus cell types…
Abstract Number: 1550 • ACR Convergence 2025
Real-World Outcomes of Anifrolumab in Systemic Lupus Erythematosus Patients at Toronto Lupus Program
Virginia Carrizo Abarza¹, Qixuan Li², Teresa Semalulu³, Justin Smith³, Pankti Mehta⁴, Fadi Kharouf⁵, Dafna D. Gladman⁶, Laura Whitall Garcia⁷ and Zahi Touma³, ¹Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ⁵University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody targeting the type I interferon receptor subunit 1 (IFNAR1), blocking interferon activity and reducing disease activity in…
Abstract Number: 1532 • ACR Convergence 2025
Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus
Hanwei Wang¹, Yue Xie², Guojiao Yang³, Lu Han³, Jiangtao Ren⁴, Yali Zhou⁴, Wengang Ge³, Jan Davidson-Moncada⁴ and Huan Zhou⁵, ¹The Third People’s Hospital of Bengbu, Beng bu, China (People's Republic), ²Bioheng Therapeutics Limited, Nan Jing Shi, China (People's Republic), ³Bioheng Therapeutics Co., Limited, Nanjing, China (People's Republic), ⁴Bioheng Therapeutics Co., Limited, Nan Jing, China (People's Republic), ⁵Clinical Research Hospital of the First Affiliated Hospital of Anhui Medical University, Hefei, China (People's Republic)
Background/Purpose: SLE is characterized by B cell activation, autoantibody production and autoreactivity. Recently, CAR-T therapy has emerged as a promising strategy to deplete autoreactive B…
Abstract Number: 1513 • ACR Convergence 2025
Race, Renal Failure, and Risk: A five-to-ten year retrospective cohort study of Racial differences in outcomes of patients with dialysis-dependent Lupus nephritis
Ufuoma Mamoh¹, Queeneth Edwards², Chukwuemelie Okeke³, Justin Riley Lam⁴, Soziema Salia⁵ and Christhopher Haas⁶, ¹Medstar Health Georgetown University Internal Medicine Residency Program, Baltimore, MD, ²Georgia Southern University, Statesboro, GA, ³Maimonides Medical Center, Brooklyn, NY, ⁴Albert Einstein Medical Center, Philadelphia, PA, ⁵MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, MD, ⁶MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that disproportionately affects racial and ethnic minority populations, particularly Black/African American and Hispanic/Latino individuals. In…
Abstract Number: 1490 • ACR Convergence 2025
Vitamin D Deficiency and Its Relationship with Inflammatory Biomarkers in SLE: A Focus on Neutrophil-to-Lymphocyte Ratio
judith hernández-Sánchez¹, Beatriz Tejera Segura², Luis Bausá Gimeno¹, Doryan García Olivas¹, Patricia González Terrats¹, MA Acosta Mérida¹, Diana Botello Corzo¹, Daniel Batista perdomo¹, Sergio Machin González¹, F Javier Nóvoa Medina¹ and Jose Angel Hernandez³, ¹Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las palmas, Spain, ²Hospital Insular de Gran Canaria, Las palmas, Spain, ³Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran CanariaHospital, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs. Vitamin D levels have been associated with disease activity in…
Abstract Number: 1473 • ACR Convergence 2025
Comparison of Three Different Double-Stranded DNA Antibody Assays in the Diagnosis of Systemic Lupus Erythematosus
Anika Morgado¹, Sowmika Rao², Lili Tao¹ and Narender Annapureddy³, ¹Vanderbilt University Medical centre, Nashville, ²Vanderbilt University Medical Center, Nashville, ³Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Double-stranded DNA (dsDNA) antibodies are among the most specific biomarkers for systemic lupus erythematosus (SLE). They are associated with disease activity and are incorporated…
Abstract Number: 1286 • ACR Convergence 2025
Response to Hydroxychloroquine in Immune Thrombocytopenia in Childhood-Onset Systemic Lupus Erythematosus
Hamada Natour¹, Y. Ingrid Goh¹, Daniela Dominguez², Nicholas Gold¹, Lawrence Ng³, Andrea Knight⁴, Earl Silverman¹, Brian Feldman¹, Linda Hiraki¹ and Deborah Levy¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, Canada, ³The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: The management of immune thrombocytopenia in childhood-onset systemic lupus erythematosus (cSLE) is not standardized. We examined the efficacy and safety of hydroxychloroquine (HCQ) as…
Abstract Number: 1118 • ACR Convergence 2025
Increased Risk of Azathioprine-Induced Leukopenia in Patients with Systemic Lupus Erythematosus: A 10-Year Retrospective Cohort Study at a Quaternary Care Hospital in Thailand
Settawut Buadee¹, Kittikorn Wilasrusmee¹, Tanakrit Kamonsumlitpon¹, Sirirat Charuvanij², Ekapun Karoopongse³ and Praveena Chiowchanwisawakit⁴, ¹Medical Student, Faculty of Medicine, Siriraj Hospital, Mahdol University, Bangkok, Thailand, ²Division of Rheumatology, Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand, ³Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand, ⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand
Background/Purpose: To estimate the incidence and identify associated factors of azathioprine (AZA)-induced leukopenia.Methods: A retrospective cohort study was conducted on 1,062 adult patients with non-malignant…
Abstract Number: 0985 • ACR Convergence 2025
Lupus Skin Shapes a Distinct Inflammatory Milieu that Drives the Skewing of Treg and inflammatory T cells
Hiroshi Kato¹, Lin Zhang¹, Mehrnaz Gharaee-Kermani², Amy Hurst¹, Rachael Bogle³, Alex Tsoi³, Johann Gudjonsson² and J. Michelle Kahlenberg², ¹Michigan Medicine, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Holland, OH
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a frequent manifestation of systemic lupus erythematosus (SLE) and remains an important contributor to morbidity in lupus patients. Despite…
Abstract Number: 0933 • ACR Convergence 2025
Spatial Transcriptomics Reveal Altered Immune Dynamics Regulating Placental Development In a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Yunwei Xia¹, Paul Hoover², Arnon Arazi³ and Anne Davidson¹, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Brigham and Women's Hospital, Boston, MA, ³Feinstein Institutes for Medical Research, Acton, MA
Background/Purpose: TLR8 has been implicated in adverse outcomes of human pregnancy. We previously reported a mouse model of spontaneous aPL-induced pregnancy loss in Sle1 mice…
Abstract Number: 0662 • ACR Convergence 2025
Efficacy Across Baseline Characteristic Subgroups in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib: Results From SLEek, a Phase 2 Randomized
Marta Mosca¹, Karen H. Costenbader², Amit Saxena³, Michelle Petri⁴, Andrea Rubbert-Roth⁵, Karim Masri⁶, Christopher Saffore⁷, Ling Cheng⁸ and Joan Merrill⁹, ¹University of Pisa, Pisa, Pisa, Italy, ²Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁴Johns Hopkins University School of Medicine, Timonium, MD, ⁵Division of Rheumatology and Immunology, Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., waukegan, IL, ⁸AbbVie, North, IL, ⁹Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK
Background/Purpose: Clinical and immunological manifestations of systemic lupus erythematosus (SLE) vary widely across patients, complicating diagnosis and treatment (1,2). Upadacitinib (UPA), an oral selective JAK…
Abstract Number: 0638 • ACR Convergence 2025
Prevalence of lupus nephritis, end stage kidney disease, avascular necrosis, and mortality in systemic lupus erythematosus in the recent era
Takehiro Nakai¹, Sho Fukui², Yukihiko Ikeda³, Masei Suda⁴, Hiromichi Tamaki¹, mitsumasa kishimoto⁵ and Masato Okada⁶, ¹Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ²Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ³St Luke's international hospital in Japan, Tokyo, Japan, ⁴Suwa Central Hospital, Nagano, Japan, ⁵Kyorin University School of Medicine, Tokyo, Japan, ⁶St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease associated with an increased risk of chronic kidney disease (CKD), avascular necrosis (AVN), and mortality. Despite…
Abstract Number: 0618 • ACR Convergence 2025
Therapeutic landscape of systemic lupus erythematosus pure membranous nephropathy: a nationwide population-based study
Kevin Chevalier¹, Romain Brousse², alexandre karras³, Nathalie Costedoat-Chalumeau⁴, Julien Dang⁵, Maxence Taillar⁶, Noémie JOURDE-CHICHE⁶, Charles Ronsin⁷, Moglie Le Quintrec-Donnette⁸, Marie Julien⁹, Antoine Huart¹⁰, Aymeric Couturier¹¹, Pierre Pommerolle¹², Céline Lebas¹³, Antoine Coussement¹⁴, Marion Chapal¹⁵, Christophe Barba¹⁶, Alexia Gauffre¹⁷, Maxime Teisseyre¹⁸, Johan Noble¹⁹, Chloé Comarmond²⁰, Eve Vilaine²¹, Jean-François Augusto²², Aurélie Hummel²³, Evangeline Pillebout²⁴, Jean-Michel Halami²⁵, Olivier Moranne²⁶, Eric Daugas²⁷, Jean-Jacques Boffa² and Emmanuel Esteve², ¹Université Paris Cité, Montrouge, France, ²Tenon hospital, Paris, France, ³HEGP - assistance publique hopitaux de paris, paris, France, ⁴Cochin hospital, Paris, France, ⁵Bicêtre hospital, Kremlin Bicêtre, France, ⁶Centre de Néphrologie et Transplantation Rénale, Hôpital de la Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France., Marseille, France, ⁷Department of Nephrology and Immunology, Nantes University Hospital, Nantes, France., Nantes, France, ⁸Service de Néphrologie-Soins Intensifs-Dialyse et Transplantation, Hôpital Lapeyronie, Montpellier, France., Montpellier, France, ⁹Service de néphrologie, CHU de la Réunion, Saint-Denis, France., Saint-Denis, France, ¹⁰Département de Néphrologie et Transplantation d’Organes, Axe Transplantation – Immunité – Environnement, CHU de Toulouse, France, Toulouse, France, ¹¹Nephrology Unit, American Hospital of Paris, Neuilly-sur-Seine, France, Neuilly-sur-seine, France, ¹²Department of Nephrology, Dialysis, and Transplantation, University of Picardie Jules Verne, Amiens University Hospital, Amiens, France., Amiens, France, ¹³Service de Néphrologie et Transplantation rénale, Centre Hospitalier Régional Universitaire de Lille, Lille, France., Lille, France, ¹⁴Service de Néphrologie, CHU de Dijon, Dijon, France., Dijon, France, ¹⁵Departement of Nephrology, Hospital of Vendée, La Roche-Sur-Yon, ⁸⁵⁰⁰⁰, France., La Roche-sur-yon, France, ¹⁶Department of Nephrology and Nutrition, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre- Bénite, France, Lyon, France, ¹⁷Service de néphrologie, CHU de Rouen, Rouen, France, Rouen, France, ¹⁸Département de Néphrologie, Dialyse et Transplantation, CHU de Nice, Université Côte d'Azur, France., Nice, France, ¹⁹Department of Nephrology, Grenoble-Alpes University Hospital, Grenoble, France., Grenoble, France, ²⁰Internal Medicine Department, Département Médico-Universitaire INVICTUS, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris (APHP).Nord-Université Paris-Cité, ⁷⁵⁰¹⁰ Paris, France., Paris, France, ²¹Ambroise Paré hospital, Boulogne, France, ²²Service de Néphrologie-Dialyse-Transplantation, Université d'Angers, CHU Angers, Angers, France., Angers, France, ²³Department of Nephrology, Necker-Enfants Malades Hospital, APHP, Paris, France., Paris, France, ²⁴Nephrology Unit, Saint Louis Hospital, Paris, France., Paris, France, ²⁵Department of Nephrology, UMR¹³²⁷ ischemia, INI-CRCT, Tours University Hospital, Tours University, Tours, France., Tours, France, ²⁶Service de Néphrologie, dialyse et aphérèse, CHU de Nîmes, IDESP Universite de Montpellier, France, Montpellier, France, ²⁷Department of Nephrology, Hospital Bichat - Claude-Bernard, Paris, France
Background/Purpose: Renal involvement is a major prognostic factor in systemic lupus erythematosus. Pure lupus membranous nephropathy (PLMN, class V) represents 5–20% of lupus nephritis cases,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].